Use of Generic Vs Branded Drugs in Enteric Fever – A Prospective and Comparative Study
Background: The concept of generic prescription is widely accepted in various parts of the world. Nevertheless, it has failed to gain popularity in India due to factors such as non-availability and distrust on the product quality. Aim: To study cost-effective and cost-benefit analysis of antibiotic prescription in patients who had enteric fever and were given intravenous ceftriaxone. Methods: This was a prospective observational study conducted in a tertiary care cenre at World College of Medical Science and Research, Jhajjar, Haryana. 65 patients who have been diagnosed with enteric fever and were prescribed ceftriaxone were studied and their prescriptions were analyzed. 5 brands of most commonly prescribed ceftriaxone injections were chosen to analyse cost effective and cost-benefit analysis. Results: Out of 65 patients, 40 were females and 25 were males, diagnosed with enteric fever. Maximum number of patients were seen between age group of 36-50 years (38) and minimum patients belonged to age group of more than 65 years. Analysis of prescriptions revealed that majority of the patients were prescribed Branded drugs 53 (82%) than were prescribed generic drugs 12 (18%). The analysis of the cost of single dose of inj. ceftriaxone revealed that branded drugs were 8.52 % to 180.81% more in comparison with generic IV ceftriaxone. Conclusion: The cost of most commonly prescribed branded drugs was significantly higher than generic drug and prescribing branded drugs was associated with failure to take complete treatment as prescribed by treating physician.
2. Henry D, Lopert R. Pharmacoeconomics and policy decisions:the Australia health care system. Clin Ther. 1999 May;21(5):909-15.
3. Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004 Mar-Apr;17(2):80-3.
4. Kesselheim AS, Avorn J, Sarpatwari A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30;316(8):858-71.
5. Tompkins RK, Wood RW, Wolcott BW, Walsh BT. The effectiveness and cost of acute respiratory illness medical care provided by physicians and algorithm-assisted physicians' assistants. Med Care. 1977 Dec;15(12):991-1003.
6. Shargel L, Isadore K, editors. Generic drug productdevelopment: solid oral dosage forms. CRC Press; 2013.
7. Shah US. Regulatory strategies and lessons in the development of biosimilars. In: Pharmaceutical sciences encyclopedia. Wiley; 2010.
8. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ Perceptions Of Generic Medications: Although most Americans appreciate the cost-saving value of generics, few are eager to use generics themselves. Health affairs (Project Hope). 2009;28(2):546-556. doi:10.1377/hlthaff.28.2.546.
9. Gallelli L, Palleria C, De Vuono A, et al. Safety and efficacy of generic drugs with respect to brand formulation. Journal of Pharmacology & Pharmacotherapeutics. 2013;4(Suppl1):S110-S114.
10. Medical council of india, code of ethics regulations 2002http://www.mciindia.org/RulesandRegulations/Codeof Medical EthicsRegulations2002.aspx.
11. Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. Definition and Classification of Generic Drugs Across the World. Applied Health Economics and Health Policy. 2015;13(Suppl 1):5-11.
12. Sicras-Mainar A, Navarro-Artieda R. Physicians’ and patients’ opinions on the use of generic drugs. Journal of Pharmacology & Pharmacotherapeutics. 2012;3(3):268-270.
13. 13. Plianbangchang P, Jetiyanon K, Suttaloung C, Khumchuen L. Physicians’ generic drug prescribing behavior in district hospitals: a case of Phitsanulok, Thailand. Pharmacy Practice. 2010;8(3):167-172.
14. Allenet B, Golay A. What are patients' attitudes towards generic drugs? The example of metformin. Rev Med Suisse. 2013 May 8;9(385):1005-9.
15. Privitera MD. Generic Antiepileptic Drugs: Current Controversies and Future Directions. Epilepsy Currents. 2008;8(5):113-117.